David Johnson

Dr. Johnson is an inventor, entrepreneur, and expert in single-cell immunology, with a track record of bringing new medical technologies to market. Since founding GigaGen, Dr. Johnson has raised approximately $52 million in partnerships with established pharmaceutical companies, including Grifols, Novartis, and Merck. He has also served as principal investigator for 16 grants totaling over $10 million from the National Science Foundation, National Cancer Institute and National Institute of Allergy and Infectious Diseases, including seven Phase 2 projects. Prior to GigaGen, Dr. Johnson was a founding member and chief operating officer of Natera (NASDAQ: NTRA), a reproductive molecular diagnostics firm. At Natera, Dr. Johnson was responsible for all clinical operations, laboratory research, clinical studies and clinical product development. Previously, he served as a project director at the Stanford Human Genome Center. Dr. Johnson holds a B.S. in Biology from Duke University, a Ph.D. in Genetics from Stanford University and an MBA from the Haas School of Business at the University of California, Berkeley. Dr. Johnson is widely published in journals such as Science, Nature Methods, Blood and mAbs.